VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
WGS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
WGSGeneDx Holdings Corp.
$47.29$1.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. WGS
  4. Financial Ratios

GeneDx Holdings Corp. (WGS) Financial Ratios

Latest Ratios: P/E Ratio -12.7x · EV/EBITDA N/A · ROE -7.6%. (2020–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

WGS Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Market Cap$1.4B$3.5B$2.1B$67M$89M$482M$2.0B
Enterprise Value$1.4B$3.5B$2.1B$87M$29M$114M$2.0B
P/E Ratio →-12.72——————
P/S Ratio3.068.186.770.330.382.2711.43
P/B Ratio4.1311.358.430.290.351.24467.16
P/FCF—245.23—————
P/OCF42.38105.10—————

P/E links to full P/E history page with 30-year chart

WGS EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
EV / Revenue—8.206.870.430.120.5411.07
EV / EBITDA—261.19—————
EV / EBIT———————
EV / FCF—245.80—————

WGS Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Gross Margin69.7%69.7%63.6%44.4%-11.4%-7.8%2.2%
Operating Margin-2.8%-2.8%-7.6%-89.2%-284.5%-210.3%-134.9%
Net Profit Margin-4.9%-4.9%-17.1%-86.8%-233.9%-115.6%-134.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
ROE-7.6%-7.6%-22.1%-73.0%-171.1%-125.0%-5500.0%
ROA-4.5%-4.5%-12.5%-36.5%-99.9%-60.9%-95.9%
ROIC-3.0%-3.0%-6.6%-61.4%-468.4%——
ROCE-3.0%-3.0%-6.4%-47.5%-156.4%-141.4%-135.8%

WGS Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Debt / Equity0.370.370.470.530.300.089.86
Debt / EBITDA8.438.43—————
Net Debt / Equity—0.030.130.09-0.24-0.95-14.79
Net Debt / EBITDA0.610.61—————
Debt / FCF—0.57—————
Interest Coverage-7.32-7.32-16.36—-142.66-85.56-96.55

WGS Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Current Ratio2.462.463.613.101.474.772.37
Quick Ratio2.342.343.422.951.384.442.03
Cash Ratio1.571.572.582.210.953.951.47
Asset Turnover—0.820.730.480.430.380.71
Inventory Turnover9.279.2710.4312.8219.136.847.02
Days Sales Outstanding—63.4944.9759.1367.4145.6965.81

WGS Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Dividend Yield———————
Payout Ratio———————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Earnings Yield———————
FCF Yield—0.4%—————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$27M$27M$24M$10M$3M$6M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetAdequate
Cash FlowDeteriorating
Top Statement Risk

Persistent operating losses and cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Turnaround Multiples Price Skepticism Not Growth

Based on reported figures, WGS trades at a trailing P/E of -13.96 and a forward P/E of 518.70, with P/S of 3.36 and P/B of 4.53, a configuration that signals the market is pricing sustained profitability as uncertain rather than imminent.

The negative trailing P/E reflects GAAP losses, so earnings-based valuation is not meaningful today, and the extreme forward P/E of 518.70 implies that the consensus earnings base remains near breakeven. Relative to peers, the P/S of 3.36 sits well below the P/B-driven premiums of PACB and NTRA, suggesting the market values WGS more as a revenue-generating lab than as a high-multiple data platform. Investors should monitor whether the Q4 adjusted net income step-up embedded in guidance is achieved, since it is the principal input that would justify a shift to earnings-based multiples.

Gross Margin Strength Masked by Operating Losses

As reported in quarterly statements, WGS's gross margin expanded from 60.9% in Q2 2024 to 69.9% in Q3 2026, yet the operating margin of -8.5% in Q3 2026 shows that operating expenses still absorb the gross profit.

The gross margin trajectory is the most encouraging element of the profitability profile, and it compares favorably with peer Natera's 64.8%, suggesting a higher-value test mix or improved reimbursement realization. However, the operating margin has swung from -25.6% in Q1 2026 to -8.5% in Q3 2026, and the path toward breakeven depends on continued SG&A discipline rather than further gross margin gains. Net margin of -10.0% in Q3 2026 remains heavily influenced by non-operating and one-time items, so operating margin is the more reliable gauge of earning power until those items are isolated.

Returns Negative but Improving from Trough

Based on reported ratios, ROIC improved from -5.7% in Q1 2026 to -2.2% in Q3 2026 and ROE from -22.5% to -5.0%, indicating the capital base is being used more productively though still destroying value.

The return trend is directionally positive, but the sustained negative ROIC means the company is not yet earning its cost of capital on invested funds. ROE's recovery is partly a function of equity rebuilding, which lifted the denominator, so the ROE improvement should not be read purely as operational progress. Relative to peer CDNA, which generates a positive 34.1% ROE, WGS remains structurally behind, and the gap is likely to persist until operating margins turn positive.

Debt Build Outpacing Equity Recovery

According to reported quarterly figures, WGS's debt-to-equity ratio rose from 0.39 in Q3 2025 to 0.88 in Q3 2026, while interest coverage remains negative at -5.91, meaning operating earnings do not yet cover interest expense.

The rise in leverage over the past year suggests the balance sheet is being funded increasingly by borrowing while the company continues to burn cash, which warrants close attention. Negative interest coverage indicates that debt service currently depends on the cash reserve rather than operating income, and the D/EBITDA ratio is unavailable in recent quarters, limiting a complete assessment. Investors should monitor refinancing terms and whether leverage stabilizes as operating losses narrow.

Working Capital Cycle Lengthening Under Pressure

Based on reported figures, WGS's cash conversion cycle stretched from 42 days in Q1 2025 to 104 days in Q3 2026, driven primarily by a rise in days inventory outstanding to 66 and a decline in days payables to 11.

The lengthening cycle is a notable negative signal, as it implies more capital is tied up in inventory and receivables while supplier financing has contracted. The sharp drop in DPO from 37 to 11 days suggests the company has less supplier credit to lean on, which increases the working capital burden on operating cash flow. This pattern is consistent with the working capital drag observed in prior cash flow findings and warrants monitoring of receivable collection timing.

Peer Comparison Flatters Gross Margin Narrative

Based on reported ratios, the most commonly misapplied metric for WGS is gross margin, which as reported stands near 69.9% in Q3 2026 but tells little about earning power for a lab whose costs sit largely in fixed operating expense.

Gross margin is often read as proof of a scalable diagnostic franchise, yet for WGS the gap between a 69.9% gross margin and an operating margin of -8.5% shows that sequencing economics do not translate into profit without SG&A leverage. Analysts should instead anchor on operating margin trajectory and cash conversion, adjusting for stock-based compensation of $8.3M in Q3 2026 to judge the underlying cash burn. This suggests the gross margin headline may overstate the near-term investment case until operating expense discipline is demonstrated.

Download Financial Ratios Data

Includes 30+ ratios · 6 years · Updated daily

Consensus & Technical Research Suite
Open WGS Terminal

WGS Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

WGS — Frequently Asked Questions

Quick answers to the most common questions about buying WGS stock.

What is GeneDx Holdings Corp.'s P/E ratio?

GeneDx Holdings Corp.'s current P/E ratio is -12.7x. This places it at the 50th percentile of its historical range.

What is GeneDx Holdings Corp.'s ROE?

GeneDx Holdings Corp.'s return on equity (ROE) is -7.6%. The historical average is -79.8%.

Is WGS stock overvalued?

Based on historical data, GeneDx Holdings Corp. is trading at a P/E of -12.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are GeneDx Holdings Corp.'s profit margins?

GeneDx Holdings Corp. has 69.7% gross margin and -2.8% operating margin.

How much debt does GeneDx Holdings Corp. have?

GeneDx Holdings Corp.'s Debt/EBITDA ratio is 8.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.